Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Non-Current Assets (2016 - 2025)

Rocket Pharmaceuticals' Non-Current Assets history spans 10 years, with the latest figure at $137.7 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 7.89% year-over-year to $137.7 million; the TTM value through Dec 2025 reached $568.5 million, down 6.72%, while the annual FY2025 figure was $137.7 million, 7.89% down from the prior year.
  • Non-Current Assets for Q4 2025 was $137.7 million at Rocket Pharmaceuticals, down from $140.4 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $188.1 million in Q4 2023 and bottomed at $104.7 million in Q1 2021.
  • The 5-year median for Non-Current Assets is $145.2 million (2025), against an average of $138.5 million.
  • The largest annual shift saw Non-Current Assets surged 78.87% in 2022 before it dropped 20.52% in 2024.
  • A 5-year view of Non-Current Assets shows it stood at $105.0 million in 2021, then soared by 78.87% to $187.7 million in 2022, then rose by 0.2% to $188.1 million in 2023, then decreased by 20.52% to $149.5 million in 2024, then fell by 7.89% to $137.7 million in 2025.
  • Per Business Quant, the three most recent readings for RCKT's Non-Current Assets are $137.7 million (Q4 2025), $140.4 million (Q3 2025), and $143.8 million (Q2 2025).